Baidu
map

Clin Infect Dis:MSM暴露前预防HIV感染对性风险行为有何影响?

2018-09-21 吴星 环球医学

2018年8月,澳大利亚和瑞典学者在《Clin Infect Dis》发表了一项系统评价和Meta分析,考察了男男性行为者(MSM)暴露前预防(PrEP)人类免疫缺陷病毒(HIV)感染对性风险行为的影响。

2018年8月,澳大利亚和瑞典学者在《Clin Infect Dis》发表了一项系统评价和Meta分析,考察了男男性行为者(MSM)暴露前预防(PrEP)人类免疫缺陷病毒(HIV)感染对性风险行为的影响。

背景:HIV PrEP可有效降低MSM HIV风险。然而,担忧依然存在,即PrEP使用者中的风险补偿会造成避孕套使用的减少,并增加其他性疾病传播感染(STIs)的风险。研究者评估了PrEP对MSM性风险结局的影响。

方法:研究者进行了一项开放性研究的系统评价,这些研究发表于2017年8月以前,报告了HIV阴性MSM和变性女性在每天口服PrEP的情况下的性风险结局。使用随机效应Meta分析计算了汇总效应评估值,进行了定性审核和风险偏倚评估。

结果:16项观察性研究和1项开放性试验符合入组标准。总共包含4388名参与者的8项研究报告了STI患病率,总共包含5008名参与者的13项研究报告了避孕套使用的改变。暴露前预防与直肠衣原体的显著增加相关(比值比[OR],1.59;95% 置信区间[CI],1.19~2.13),与任何STI诊断的显著增加相关(OR,1.24;95% CI,0.99~1.54)。PrEP使用与STI诊断之间的相关性在后期研究中更密切。大多数研究表明,PrEP使用者中,无避孕套的性行为增加。

结论:结果强调了PrEP使用者及其性伴侣中,最小化STIs的努力的重要性。在PrEP规模放大的情况下,需要监测MSM的风险补偿,从而评估PrEP对MSM性健康的影响并制定预防策略。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947620, encodeId=eb62194e62048, content=<a href='/topic/show?id=885e12288a8' target=_blank style='color:#2F92EE;'>#MSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12288, encryptionId=885e12288a8, topicName=MSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Apr 16 01:57:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012807, encodeId=2b27201280eb4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 27 23:57:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346064, encodeId=4628346064d7, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 21 22:51:48 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346044, encodeId=9f8734604479, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 21:57:44 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947620, encodeId=eb62194e62048, content=<a href='/topic/show?id=885e12288a8' target=_blank style='color:#2F92EE;'>#MSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12288, encryptionId=885e12288a8, topicName=MSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Apr 16 01:57:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012807, encodeId=2b27201280eb4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 27 23:57:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346064, encodeId=4628346064d7, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 21 22:51:48 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346044, encodeId=9f8734604479, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 21:57:44 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1947620, encodeId=eb62194e62048, content=<a href='/topic/show?id=885e12288a8' target=_blank style='color:#2F92EE;'>#MSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12288, encryptionId=885e12288a8, topicName=MSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Apr 16 01:57:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012807, encodeId=2b27201280eb4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 27 23:57:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346064, encodeId=4628346064d7, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 21 22:51:48 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346044, encodeId=9f8734604479, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 21:57:44 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
    2018-09-21 1e1b8538m79(暂无匿称)

    不错的文章值得拥有,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1947620, encodeId=eb62194e62048, content=<a href='/topic/show?id=885e12288a8' target=_blank style='color:#2F92EE;'>#MSM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12288, encryptionId=885e12288a8, topicName=MSM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Apr 16 01:57:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012807, encodeId=2b27201280eb4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Nov 27 23:57:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346064, encodeId=4628346064d7, content=不错的文章值得拥有,, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Sep 21 22:51:48 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346044, encodeId=9f8734604479, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 21:57:44 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
    2018-09-21 医者仁心5538

    学习了

    0

相关资讯

Eurosurveillance:男男性行为会传播甲肝?

2016年下半年至2017年上半年,在欧洲数个国家间出现了一波甲肝疫情。2016年7月至2017年2月期间荷兰通报了48例男性肝炎病例;2016年7月至2017年1月期间英国报告了37例;2016年11月中旬至2017年1月底柏林方面报告了30例。

Baidu
map
Baidu
map
Baidu
map